Novo Nordisk (NOVOB DC) confirms will sell WeGovy and Ozempic on Hims & Hers (HIMS) platform
Context
Novo Nordisk's confirmation to sell WeGovy and Ozempic on the Hims & Hers platform could indicate a strategic move to expand their market reach and tap into the growing telehealth sector. This partnership may enhance revenue streams while positioning both companies collaboratively to leverage each other's customer bases. Additionally, watch for sector read-throughs in pharmaceuticals and digital healthcare as this deal unfolds.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#NOVO NORDISK A/S#NOVOB.DC#EU SESSION#US SESSION#GLOBAL EQUITIES